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In February 2011, the Korean Society for Sexual Medicine and Andrology (KSSMA) realized the necessity of developing a 
guideline on erectile dysfunction (ED) appropriate for the local context, and established a committee for the development of a 
guideline on ED. As many international guidelines based on objective evidence are available, the committee decided to adapt 
these guidelines for local needs instead of developing a new guideline. Considering the extensive research activities on ED in 
Korea, data with a high level of evidence among those reported by Korean researchers have been collected and included in the 
guideline development process. The latest KSSMA guideline on ED has been developed for urologists. The KSSMA hopes that this 
guideline will help urologists in clinical practice.
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EPIDEMIOLOGY AND RISK FACTORS FOR 
ERECTILE DYSFUNCTION
1. Epidemiology of erectile dysfunction 
　Recent epidemiological data have shown a high preva-
lence and incidence of erectile dysfunction (ED) 
worldwide. The Massachusetts Male Aging Study (MMAS), 
the first large-scale community-based study, reported that 
the prevalence of ED was 52% in men aged 40∼70 years 
living in Boston, USA.1 In that study, the prevalence of 
mild, moderate, and complete ED was reported to be 
17.2%, 25.2%, and 9.6%, respectively. The Cologne Male 
Survey, a representative European epidemiologic study, re-
ported that the prevalence of ED was 19.2% in men aged 
30∼80 years living in Cologne, Germany in a mail 
survey.2
　The Asian Men’s Attitudes to Life Events and Sexuality 
(Asian MALES), an epidemiologic study that was con-
ducted on over 10,000 men aged 20∼75 years in five 
Asian countries including the Republic of Korea 
(hereafter, ‘Korea’), demonstrated that the overall preva-
lence of self-reported ED was 6.4%.3 The prevalence of 
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self-reported ED varied depending on the country, and it 
was reported to be 8% in Korean men.3 The Global Study 
of Sexual Attitudes and Behaviors reported that 15% of 
sexually active Asian men aged 40∼80 years had ED and 
that 18% of Korean men had ED.4
　In 2004, a large-scale survey for ED was conducted by 
the KSSMA, which was a representative epidemiologic 
study conducted in Korea.5 In that study, 13.4% of 1,570 
men aged 40∼79 years, who were randomly selected in 
a stratified three-stage cluster sample of administrative dis-
tricts (gu) nationwide, replied that they suffered from ED. 
The overall prevalence of ED was shown to be 32.4% 
(mild 10.6%, moderate 10.0%, and severe 11.8%) when 
ED was defined by an International Index of Erectile 
Function (IIEF)-5 score ≤17 points.5 In a Korean study, 
which was conducted on 3,501 men aged 20 years or 
above who visited primary care physicians, the preva-
lence of ED was reported to be 36.6% (mild 24.7%, mod-
erate 10.2%, severe 1.6%) when ED was defined by an 
IIEF-5 score ≤17 points.6
2. Risk factors for erectile dysfunction 
　Risk factors for ED include age, diabetes, hyper-
tension, obesity, lack of exercise, dyslipidemia, smoking, 
depression, lower urinary tract symptoms, and pelvic 
surgery.
1) Age
　The prevalence of ED increases in proportion to age, 
which has been confirmed in international studies, such as 
the MMAS, Cologne Male Survey, and Asian MALES 
study, as well as Korean studies.1-5 In the Cologne Male 
Survey, the prevalence of ED was shown to be 53.4% in 
men in their 70s and 2.3% in men in their 30s.2 In a Korean 
sample survey, the prevalence of ED was reported to be 
4.2%, 13%, 30.1%, and 41.1% in men in their 40s, 50s, 
60s, and 70s, respectively, which rapidly increased with 
increasing age.5
2) Diabetes 
　The MMAS reported that the risk of complete ED was 
three-fold higher in diabetic patients.1 In a Korean sample 
survey, the risk of ED was reported to be 2.87-fold higher 
in diabetic patients.5 Another study, which was conducted 
on patients who visited primary care physicians, reported 
that diabetes was an independent risk factor of ED.6 The 
study demonstrated that the prevalence of complete ED 
was 6-fold higher in Korean patients with type-2 diabetes 
than in healthy subjects, and that the prevalence of ED was 
48.8%, 67.7%, and 79.3% in diabetic patients in their 
40s, 50s, and 60s, respectively. In addition, the duration of 
diabetes, fasting glucose level, and HbA1c level were as-
sociated with the severity of ED.7
3) Hypertension 
　The MMAS showed that 15% of hypertension patients 
had complete ED.1 In the MALES study, which was con-
ducted in seven western countries, the prevalence of ED 
was reported to be 26% in hypertension patients.8 In a co-
hort study that was conducted in the U.S., the prevalence 
of hypertension was 41.2% in men with ED and 19.2% in 
men without ED. After controlling for subject age, census 
region, and 9 concurrent diseases, the odds ratio was 
1.38.9 In a Korean study, the odds ratio for ED was re-
ported to be 2.97 and 4.78 in patients with hypertension 
and with heart diseases, respectively.5
4) Overweight and lack of exercise 
　The odds ratio for ED was reported to be more than 60% 
higher in overweight males than in normal weight 
males.10 For Korean men, central obesity was shown to be 
significantly correlated with ED,11 and body mass index 
(BMI) and body fat percentage were also shown to be asso-
ciated with ED.12 The MMAS showed that physical activity 
status was associated with ED and that the odds ratio for 
ED decreased by approximately 70% in men who initiated 
physical activity at their middle age, relative to that for 
men who remained sedentary when the subjects were fol-
lowed-up for more than 8 years.13
5) Dyslipidemia 
　The MMAS showed that the prevalence of ED had a neg-
ative correlation with the high density lipoprotein (HDL) 
level.1 In a study where 3,250 subjects (25∼83 years) 
without ED at their initial visit were followed-up for a peri-
od of 6∼48 months, the odds ratio for ED was 1.83 in the 
group with a total cholesterol ≥240 mg/dl than in the 
group with total cholesterol ＜180 mg/dl; whereas it was 
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shown to decrease by 70% in the group with HDL ≥60 
mg/dl compared to the group with HDL ＜30 mg/dl.14 In 
a Korean study, the odds ratio for ED was reported to be 
2.39 in patients with hypertriglyceridemia.5 
6) Smoking
　Smoking is a risk factor of ED by causing injury to the 
vascular endothelial cells. In the MMAS, the risk of com-
plete ED was shown to significantly increase in smoking 
patients with coronary artery disease or hypertension, and 
the odds ratio for ED in smokers versus non-smokers was 
1.97 in a follow-up study. In addition, passive exposure to 
cigarette smoke may act as an additional risk for ED both 
in non-smokers and smokers.1,15 In a Korean study, the 
odds ratio for ED in smokers with a smoking level of 30 
packs/year versus non-smokers was reported to be 1.36.6 
7) Depression 
　The MMAS showed that ED was associated with depres-
sive symptoms after controlling for potential confounders 
(odds ratio=1.82).16 In a follow-up study, which was con-
ducted on 1,380 males in Finland, ED was also associated 
with untreated and treated depressive symptoms. The 
prevalence odds ratio adjusted for potential confounders 
was 2.6 for untreated and 3.3 for treated depressive symp-
toms at the beginning of the follow-up. In addition, the ad-
justed incidence density ratio of depressive mood was 1.9 
in men with ED relative to those without ED.17 In Korean 
studies, the odds ratio of ED in patients with depression 
versus in those without depression was 1.6 to 3.6.5,18 
8) Benign prostatic hyperplasia and lower urinary 
tract symptoms
　In a study that was conducted on more than 10,000 sub-
jects in a group of western countries, the odds ratio for ED 
was shown to be 7.67-fold higher in patients with severe 
lower urinary tract symptoms.19 In a Korean study, benign 
prostatic hyperplasia and lower urinary tract symptom-re-
lated factors (international prostate symptom score, 
post-void residual, maximum urine flow rate) were sig-
nificantly correlated with ED.11,20
9) Pelvic surgery and radical prostatectomy 
　ED may occur after pelvic surgery for curative treatments, 
such as prostate cancer, bladder cancer, and colorectal 
cancer. In particular, ED was reported to occur in 25∼75% 
of patients who underwent radical prostatectomy.21 The 
loss and fibrosis of the cavernous smooth muscle due to 
cavernous nerve injury, as well as the lack of blood flow 
and oxygen supply due to vascular injury, are known to 
cause ED. Age and preoperative erectile function (EF) are 
the main factors that can predict the recovery of post-
operative EF. A nerve-sparing technique should be applied 
to preserve postoperative EF.22
10) Medications
　Antihypertensive drugs and psychotropic agents, such 
as antidepressants, may cause ED due to adverse drug re-
actions, and the discontinuation of such drugs does not al-
ways result in the recovery of EF. Although hypertension 
and psychiatric disorders should be treated prior to ED 
management, this potential adverse reaction, which might 
be irreversible, should be discussed before prescribing 
such medications.23 Among antihypertensive agents, diu-
retics, nonselective α-blockers, and β2-blockers may 
cause ED, but angiotensin converting enzyme inhibitors, 
calcium channel blockers, α1-blockers, and angiotensin 
receptor blockers are known to have a low risk of ED.24 
DIAGNOSIS OF ERECTILE DYSFUNCTION 
1. Basic evaluation 
　The diagnosis and clinical evaluation of ED should be 
helpful in the determination of personalized treatment op-
tions by identifying the underlying causes via the inves-
tigation of risk factors and by determining the severity of 
ED. A thorough history-taking is essential for all patients 
who suffer from ED. In addition, a physical examination 
and laboratory tests should also be conducted.
1) History 
　It is important to thoroughly review the previous disease 
history of patients and their partners. Ideally, information 
on sexual behaviors should also be obtained by interview-
ing sex partners, even though this may not be possible in 
reality. An interview with patients should be performed in 
an independent place with sufficient time and a comfort-
able environment to maintain the patient’s privacy.
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　(1) Sexual history
　The presence of any risk factors related to ED should be 
determined. It is useful to explain concurrent risk factors to 
patients in advance to help the patient’s understanding. 
The status of sexual behaviors before and after ED should 
be investigated. ED should be investigated whether it is 
transient or persistent, whether it is acute or chronic, and 
if it is accompanied by other sexual dysfunctions (ejaculat-
ion disorder, decreased sexual desire, and orgasm dis-
order). In addition, treatment methods previously con-
ducted and their efficacy should also be reviewed. The 
clinician should also inquire about erectile rigidity, erec-
tile maintenance time, and the presence of nocturnal pen-
ile tumescence. The sex-related diseases or menopause of 
partners should also be noted.
　(2) Other history
　It is necessary to determine the presence of any risk fac-
tors of cardiovascular diseases, as well as concurrent dis-
eases, such as hypertension, diabetes, and dyslipidemia. 
Any history of injury, surgery, or radiation therapy should 
be reviewed. The patient should also be checked for con-
current voiding dysfunction or sleep disorder, along with 
smoking history, drinking history, and previous and cur-
rent medications. The type, frequency, duration, and in-
tensity of current exercise are also checked.
　(3) Questionnaire
　Questionnaires that are commonly used in Korea in-
clude the IIEF and IIEF-5. The IIEF has been used since 1999 
after its Korean version was validated for its reliability and 
sensitivity.25 It is comprised of 15 questions in five do-
mains: EF, orgasm, sexual desire, intercourse satisfaction, 
and overall sexual satisfaction. It is difficult to use it in ac-
tual clinical practice as it is too long. Thus, the IIEF-5, which 
is a short version of the IIEF, is commonly used.26 The IIEF-5 
evaluates the sexual function of the past 6 months, using 
questions with score range from 0 or 1 point to 5 points. 
The IIEF-5 is useful for screening for ED and for determining 
the severity of ED. The Korean version of the IIEF-5 has a 
cutoff of 17 points, which determines ED and classifies ED 
into normal (18∼25 points), mild (14∼17 points), moder-
ate (10∼13 points), and complete ED (9 points or less) ac-
cording to the total score of the questionnaire.27
2) Physical examination
　A focused physical examination must be performed on 
every patient, with particular emphasis on the genito-
urinary, endocrine, vascular, and neurologic systems.28 
The physical examination may reveal unsuspected diag-
noses, such as Peyronie’s disease, prostatic enlargement, 
or cancer, as well as signs and symptoms indicative of 
hypogonadism.29 Digital rectal examination of the pros-
tate should be conducted in patients aged 50 years or 
higher. Height, weight, BMI, blood pressure, heart rate, 
and waist circumference should be measured.30
3) Laboratory tests
　It is recommended that laboratory tests be conducted 
selectively according to the symptoms and identified risk 
factors. The fasting glucose level, lipid profile, and testos-
terone levels should, however, be measured in all 
patients. The testosterone level should be measured be-
tween 7 and 11 a.m. If hypogonadism is suspected during 
the disease history taking and physical examination, hor-
mone tests for prolactin, luteinizing hormone (LH), and 
follicular stimulating hormone (FSH), should also be 
conducted.31 If an additional test is required for prostatic 
diseases, serum prostate specific antigen (PSA) should be 
measured.
2. Evaluation of the cardiovascular system
　It has been well known that the prevalence of car-
diovascular diseases is high in patients with ED, and that 
cardiovascular disease and ED have common risk 
factors.32 The hypothesis that ED is a harbinger of car-
diovascular disease (particularly, coronary artery disease), 
while it remains asymptomatic, but for which symptoms 
might occur later, has been recently accepted as a proven 
theory.33 Patients with coronary artery disease and their 
partners may be concerned about their sexual behaviors 
as they suspect that sexual activities might negatively af-
fect the heart. According to the recommendation of the 
Princeton Consensus Panel, patients with ED should be 
classified into three groups according to the risk of heart 
disease, and then a proper treatment plan for each patient 
should be set up to predict the risks that might occur dur-
ing sexual activities.34,35
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Table 1. Cardiac risk stratification
Low-risk group Intermediate-risk group High-risk group
Asymptomatic, ＜3 risk factors for CAD
 (excluding gender)
Mild, stable angina
Uncomplicated previous MI
LVD/CHF (NYHA class I)
Post-successful coronary artery
 revascularization
Controlled hypertension
Mild valve disease
≥3 risk factors for CAD
 (excluding gender)
Moderate, stable angina
Recent MI (2∼6 weeks)
LVD/CHF (NYHA class II)
Non-cardiac sequelae of atherosclerotic
 disease (e.g. cerebrovascular disease)
High risk arrhythmia
Unstable or refractory angina
Recent MI (＜2 weeks)
LVD/CHA (NYHA class III/IV)
Obstructive hypertrophy and other
 cardiomyopathy
Uncontrolled hypertension
Moderate-to-severe valve disease
Risk factors for CAD: age, diabetes, hypertension, obesity, dyslipidemia, smoking, sedentary lifestyle, male, familial history 
of early onset of coronary artery disease. 
CAD: coronary artery disease, MI: myocardial infarction, LVD: left ventricular dysfunction, CHF: congestive heart failure, 
NYHA: New York Heart Association.
1) Patients with cardiovascular risk factors 
　Patients with ED should be classified into low-risk, inter-
mediate-risk, and high-risk groups, according to their car-
diovascular status (Table 1).34,35 The risk factors of car-
diovascular diseases include age, being male, hyper-
tension, diabetes, smoking, dyslipidemia, a sedentary life-
style, and a familial history of early onset of coronary ar-
tery disease. Three cardiovascular risk categories can be 
used as the basis for a treatment algorithm for initiating or 
resuming sexual activity.
2) Low-risk group
　The cardiovascular system of the low-risk group is rarely 
influenced by sexual activities. Thus, the low-risk group 
does not require any additional examinations of the car-
diovascular system. This group can have sexual activities 
without any particular examination and undergo treat-
ment for ED.
3) Intermediate-risk group
　As the risk of cardiovascular diseases is uncertain in 
the intermediate-risk group, a preliminary test is required 
before engaging in sexual activities. This group may be 
reclassified into low and high-risk groups, depending on 
the result of the test. An exercise treadmill test is useful for 
this group.35 If necessary, the safety of the management 
of ED and sexual activities can be evaluated by a 
cardiologist.
4) High-risk group
　The high-risk group is in an unstable and serious cardiac 
status. Thus, sexual activities may increase the risk of heart 
disease. The high-risk group should be examined by a car-
diologist, and a treatment for the heart should be con-
ducted in advance. Sexual activities are not recommended 
unless the cardiac status becomes stabilized after treat-
ment or the safety of sexual activities is confirmed by a 
cardiologist.
3. Specific tests
　ED can be managed in most patients after they undergo 
basic tests. However, some patients need specific diag-
nostic tests. For young men with a history of pelvic or peri-
neal trauma, a specific test is required to check whether 
they could benefit from potentially curative vascular 
surgery. Specific tests are also needed for patients with pri-
mary ED or with penile deformities that might require sur-
gical correction, e.g. Peyronie’s disease. Other indications 
for specialized tests include patients with complex endo-
crine or psychiatric disorders or the request of the patient 
or his partner. Specific tests may also be conducted for 
medicolegal reasons, such as a divorce suit or sexual 
abuse.
1) Vascular studies
(1) Intracavernous injection test
　In general, 10∼20 μg of prostaglandin E1 (PGE1) is in-
jected into the corpus cavernosum, followed by audio-vis-
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ual sexual stimulation and genital self-stimulation. If neu-
rogenic or psychogenic ED is suspected, the injection 
dose should be reduced due to the risk of priapism. A pos-
itive test is defined as a rigid erection (unable to bend the 
penis) that appears within 10 minutes after the intra-
cavernous injection and lasts for 30 minutes.36 Such a re-
sponse may indicate a functional, but not necessarily nor-
mal, erection because it may coexist with arterial in-
sufficiency or veno-occlusive dysfunction.37 Therefore, its 
use as a diagnostic test for ED is limited. Its main clinical 
implication is that patients will respond to the intra-
cavernous injection program. 
(2) Penile duplex ultrasonography
　Vasodilators are injected into the corpus cavernosum, 
and then the status of penile blood flow is measured using 
a Doppler spectrum analysis. The measurement of the peak 
systolic velocity (PSV) of the cavernosal artery and the end 
diastolic velocity (EDV), which indirectly reflects penile 
blood leak, is important. The PSV is the most important 
evaluation factor. A PSV ＞30 cm/s and an EDV ＜5 cm/s 
are generally considered to be normal.36 The value ob-
tained by dividing the PSV-EDV by PSV is called a resistive 
index, and the status is assessed to be normal if the resistive 
index is ＞0.8.36 There is no need to continue vascular in-
vestigation when the duplex examination is normal. 
(3) Penile arteriography and dynamic infusion cav-
ernosometry/cavernosography
　Internal pudendal arteriography should be selectively 
conducted for patients who have abnormal findings in 
penile duplex ultrasonography and who may be candi-
dates for vascular reconstruction.38 Like penile arteriog-
raphy, dynamic infusion cavernosometry/cavernosog-
raphy (DICC), in which a needle is injected into the penile 
corpus cavernosum, should also be selectively performed 
for patients who are being considered for vascular re-
constructive surgery.38 Patients are assessed to be normal 
if the flow amount, which is required to maintain intra-
cavernous pressure ≥100 mmHg, is 3∼5 ml/min or less 
in a state of completely relaxed cavernosal smooth mus-
cle, and if the pressure reduction, which is measured for 
30 seconds in a state of halted infusion, is 45 mmHg or less 
when the intracavernous pressure reaches 150 mmHg.39
2) Pyschophysiological tests
(1) Nocturnal penile tumescence and rigidity test
　An nocturnal penile tumescence and rigidity (NPTR) 
test should be performed for at least two consecutive 
nights, and it is mainly measured using RigiscanⓇ (Timm 
Medical Technologies, Inc., Minneapolis, MN, USA; a di-
vision of Plethora Solutions Holdings, Ltd., UK). A func-
tional erectile mechanism is indicated by an erectile event 
of at least 60% rigidity recorded on the tip of the penis that 
lasts for 10 minutes or more.40 A positive NPTR test strong-
ly indicates psychogenic ED.
(2) Audiovisual sexual stimulation test
　An audiovisual sexual stimulation test can be conducted 
as a screening test with relative ease, but its clinical useful-
ness is low as many factors can cause false negativity. 
3) Neurologic test
　A neurologic test is mainly conducted for medicolegal 
purposes in order to investigate whether ED is associated 
with an accident or surgery. An objective evaluation of auto-
nomic cavernosal neurointegrity remains to be developed. 
A bulbocavernosus reflex latency test and somatosensory 
evoked potentials test, which assess the somatic nervous 
system, are typically performed, but the reference value that 
determines normal and abnormal status has not yet been 
clearly established.41
TREATMENT OF ERECTILE DYSFUNCTION
1. Goal and principle of the treatment of erectile 
dysfunction
　The primary goal of ED treatment is to enable the sat-
isfactory sexual activities of patients and their partners by 
recovering sufficient penile rigidity for sexual intercourse. 
Causes for ED, such as medication or lifestyle, are factors 
that can be addressed, and these factors should be cor-
rected before or during the treatment of ED. Changes in 
lifestyle can not only improve ED, but also improve car-
diovascular and metabolic diseases.
　Psychogenic ED, arteriogenic ED caused by trauma in 
young patients, and ED caused by hormone abnormality 
can be cured via a specific treatment. However, as the 
treatments that are applied to most patients with ED are 
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not performed based on specific causes for ED, patients 
should be informed of a variety of treatment modalities, 
and an appropriate treatment should be selected consider-
ing treatment efficacy, safety, invasiveness, cost, and the 
preference of the patient and partner.
2. Lifestyle changes and the modification of risk 
factors
　As lifestyle changes and the modification of risk factors 
are effective methods for treating ED, patients should be 
educated about such changes along with any specific 
treatment of ED, such as pharmacologic treatment. The 
potential advantages obtained by a change in lifestyle are 
particularly important in ED patients with specific car-
diovascular or endocrine diseases, such as hypertension 
or diabetes.42,43
　In the MMAS, the risk of ED was shown to decrease by 
70% in the group that started and then continued exercise 
in middle age compared to the group that did not exercise, 
and regular exercise was shown to significantly decrease 
the incidence of ED in a follow-up study that was con-
ducted for 8 years or longer.13 In a prospective, random-
ized study that was conducted on obese men who had ED 
without concurrent disease for two years, systematic ex-
ercise and weight loss brought normal EF in approx-
imately one third of the subjects.44 In addition, a random-
ized study reported that regular aerobic exercise im-
proved the efficacy of phosphodiesterase type 5 (PDE5) 
inhibitors.45 However, a further long-term, prospective 
study is required on a larger scale in order to investigate 
the positive effects of lifestyle changes and risk factor con-
trol on ED.
3. Curable causes
1) Hormones
　Endocrine disorders, such as hypogonadism, hyper-
thyroidism/hypothyroidism, and hyperprolactinemia, may 
become curable causes for ED.
(1) Hypogonadism
　Patients should be diagnosed with hypogonadism if they 
have clinical symptoms and biochemical evidence related 
to testosterone deficiency, such as decreased sexual desire 
and a low serum testosterone level. If patients with ED have 
hypogonadism, they are indicated for testosterone replace-
ment treatment.46 Various recommendations have been 
given for the diagnosis and treatment of late onset hypo-
gonadism (LOH) in elderly men. A revision of the conven-
tional recommendation has been presented by the Korean 
Society for Aging Male Research (KOSAR) in order to re-
flect the Korean context.47
　As the serum testosterone level has diurnal variation, it 
should be measured from a blood sample collected be-
tween 7 and 11 a.m. If a patient has a serum total testos-
terone level ≥12 nmol/L (346 ng/dl), or free testosterone 
≥250 pmol/L (72 pg/ml), testosterone replacement treat-
ment is not required. If a patient has total testosterone ≤8 
nmol/L (231 ng/dl) or free testosterone ≤180 pmol/L (52 
pg/ml) with reference to the data obtained from young 
men, testosterone replacement treatment is required. If 
patients have a total testosterone level of 8∼12 nmol/L, 
they may receive testosterone replacement treatment un-
less other causes are observed.47
　In a meta-analysis of 17 randomized studies that were 
conducted on ED patients to investigate the effect of tes-
tosterone replacement treatment, the result showed that 
EF was further improved by testosterone replacement 
when the testosterone level before treatment was lower.48 
However, the recovery of EF is not always observed in all 
patients via testosterone replacement alone, and multiple 
factors are involved in the pathogenesis of ED if the pa-
tient’s age increases. Thus, it should be kept in mind that 
the effect of testosterone replacement treatment is rela-
tively less in elderly patients than in young patients.49
(2) Hyperthyroidism/Hypothyroidism
　Both hyperthyroidism and hypothyroidism may cause 
decreased sexual desire and ED. Ejaculation disorder is 
known to be more frequently observed in hyper-
thyroidism and hypothyroidism.50 As the normalization of 
thyroid function may result in the recovery of sexual dys-
function, a priority should be given to the treatment of thy-
roid dysfunction.50
(3) Hyperprolactinemia
　Hyperprolactinemia may cause ED, decreased sexual 
desire, and anorgasmia. An increase in the blood prolactin 
level commonly accompanies the deficiency in testoster-
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Table 2. Pharmacokinetic data for the five PDE5 inhibitors used to treat erectile dysfunction in Korea
Parameter
PDE5 inhibitors
Sildenafil
(100 mg)
Tadalafil
(20 mg)
Vardenafil
(20 mg)
Udenafil
(200 mg)
Mirodenafil
(100 mg)
Avanafil
(200 mg)
Tmax (h)
T1/2 (h)
Action duration (h)
Cmax (μg/L)
AUC (μg/h/L)
Protein binding (%)
Bioavailability (%)
0.8∼1
2.6∼3.7
0.5∼4
560
1,685
96
41
2
17.5
1∼36
378
8,066
94
NA
0.9
3.9
0.5∼5 
18.7
56.8
94
15
1.5
9.88
0.5∼12 
1,138
7,898
NA
NA
1
2.5
0.5∼4
NA
NA
NA
24∼43
0.5
10.6
6
5,161
10,867
99
NA
PDE5: phosphodiesterase type 5, Tmax: time to maximum plasma concentration, T1/2: terminal half-life, Cmax: maximum plasma 
concentration, AUC: area under the curve, NA: not available.
one by inhibiting LH secretion. Prolactin measurement is 
recommended in men with decreased sexual desire. 
Hyperprolactinemia is mainly caused by stress, drugs such 
as potent sedatives, and chronic renal failure. However, 
the possibility of the prolactin-secreting pituitary gland tu-
mor also exists, even though it is very rare. In the case of 
persistent hyperprolactinemia for unknown reasons, pa-
tients should be referred to the department of 
endocrinology.
2) Arteriogenic erectile dysfunction after trauma 
　If arteriogenic ED occurs in young patients after pelvic 
or perineal injury, arterial reconstruction surgery can be 
conducted when the focal narrowing is observed by 
penile duplex ultrasonography and selective penile arte-
riography, and when the veno-occlusive function is nor-
mal in DICC. These patients should have no other arte-
rial or neurological risk factors. The long-term success 
rate was reported to be 60∼70% in patients properly 
selected.51 Venous surgery for veno-occlusive dysfunc-
tion is no longer recommended due to poor long-term 
results.52
3) Psychogenic erectile dysfunction 
　It is recommended that ED patients and their partners 
receive education and a consultation during the pharma-
cologic treatment of ED. The education should include 
the mechanism of penile erection using educational ma-
terials for better understanding, and should emphasize 
that ED can be cured. It is generally known that psycho-
therapy requires a long time and its effect varies.
4. First-line treatments 
1) Phosphodiesterase type 5 inhibitors 
　When men are sexually stimulated, nitric oxide (NO) is 
released from the nerve terminal and vascular endothelial 
cells of the penile erectile tissues. NO diffuses into the ad-
jacent penile cavernosal smooth muscle, increases the 
synthesis of cyclic guanosine monophosphate (cGMP), 
and decreases the cellular calcium concentration, thereby 
inducing the relaxation of penile cavernosal smooth mus-
cle cells and penile erection. PDE5, which is abundant in 
penile erectile tissues, is an enzyme that degrades cGMP. 
PDE5 inhibitors competitively inhibit the activity of PDE5, 
thereby reinforcing penile erection by increasing the 
cGMP concentration in the erectile tissues. PDE5 in-
hibitors that are currently available in the Korean market 
include sildenafil, tadalafil, vardenafil, udenafil, mir-
odenafil, and avanafil. The pharmacokinetic data of these 
six drugs are presented in Table 2. 
(1) Sildenafil
　Sildenafil is an oral PDE5 inhibitor that was first released 
into the market in 1998. It is available in doses of 25 mg, 50 
mg, and 100 mg. A 50 mg dose is generally recommended 
as an initial dose, and the dose should be increased or de-
creased according to the efficacy and adverse events of the 
drug. It has a half-life of approximately 3 hours in the blood. 
Its efficacy is observed approximately 30∼60 minutes af-
ter oral administration, and then lasts for approximately 4 
hours. A high-fat diet delays sildenafil absorption and re-
duces its blood concentration.53 Alcohol does not affect the 
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pharmacokinetics of sildenafil. In a meta-analysis of the re-
sult of a placebo-controlled, double-blind study, which 
was conducted on more than 3,000 patients, the result of 
an assessment using the global assessment question (GAQ; 
Has the treatment you have been taking over the past study 
interval improved your erections?) showed that EF im-
proved in 76% of the sildenafil group and in 22% of the pla-
cebo group during a study period of 12 weeks. In addition, 
EF improved in 65% of patients who had severe ED based 
on the IIEF questionnaire after sildenafil administration, 
whereas it was improved in 12% of the placebo group.54 
Sildenafil administration also showed a successful treat-
ment outcome in diabetic patients. The score on questions 
3 (frequency of penetration) and 4 (frequency of maintain-
ing an erection after penetration) of the IIEF questionnaire 
was shown to be 3.61 and 3.25 points, respectively, in the 
sildenafil group, but only 2.71 and 2.19 points, re-
spectively, in the placebo group, which showed that the 
scores were significantly higher in the sildenafil group than 
in the placebo group.55
　In a Korean study that was conducted on 133 patients, 
who had ED based on various causes, the results of assess-
ing the primary efficacy endpoints, that is, the scores for 
questions 3 (frequency of penetration) and 4 (frequency of 
maintaining an erection after penetration) of the IIEF ques-
tionnaire, showed that the scores on questions 3 and 4 of 
the IIEF questionnaire were shown to be 4.19 and 3.74 
points, respectively, in the sildenafil group that received 
sildenafil for 8 weeks, but 2.67 and 2.07 points, re-
spectively, in the placebo group, which showed that EF 
was significantly improved in the sildenafil group.56 
(2) Tadalafil
　Tadalafil is available in doses of 10 mg and 20 mg, and 
a dose of 5 mg, which was developed for daily admin-
istration, has been recently released onto the market. The 
most significant feature of tadalafil is that its efficacy lasts 
longer compared to the other PDE5 inhibitors. It has a 
blood half-life of approximately 17.5 hours and has effi-
cacy that starts approximately 30 minutes after drug ad-
ministration and lasts for 36 hours. Tadalafil absorption is 
rarely affected by food, and alcohol does not affect the 
pharmacokinetics of tadalafil.57 In a 12-week dose-re-
sponse study, the result of efficacy assessment, using the 
GAQ questions, showed that EF was improved in 67% of 
the 10 mg tadalafil group and in 81% of the 20 mg tadalafil 
group, but in 35% of the placebo group.58 Tadalafil admin-
istration was also effective in diabetic patients; the IIEF 
score after drug administration increased by 7.3 points in 
the tadalafil group and by 0.1 point in the placebo group, 
showing a significant increase in the tadalafil group.59 
　In a Korean study that was conducted on 121 patients 
who had ED based on various causes, the result of assess-
ing the primary efficacy endpoints, such as the EF domain 
of the IIEF, Sexual Encounter Profile question 2 (SEP2; 
Were you able to insert your penis into your partner’s vagi-
na?), and Sexual Encounter Profile question 3 (SEP3; Did 
your erection last long enough for you to have successful 
intercourse?), showed that the IIEF EF domain score was 
23.2 points and 15.4 points in the tadalafil and placebo 
groups, respectively, after drug administration, that the 
positive reply rate for the SEP question 2 was 85.4% and 
67.7% in the tadalafil and placebo groups, respectively, 
and that the positive reply rate for the SEP question 3 was 
71.2% and 31.4% in the tadalafil and placebo groups, re-
spectively, which showed a significant improvement in EF 
in the tadalafil group.60
(3) Vardenafil
　Vardenafil is available in doses of 10 mg and 20 mg. It 
has a blood half-life of approximately 3.9 hours, and its ef-
fect starts approximately 30 minutes after drug admin-
istration and lasts for 5 hours. A high-fat diet delays varde-
nafil absorption and reduces its blood concentration. 
Alcohol does not affect the pharmacokinetics of var-
denafil.61 From a meta-analysis of the results of a dou-
ble-blind, placebo-controlled study, which was con-
ducted on more than 4,000 patients, the result of efficacy 
assessment using the GAQ questions showed that EF was 
improved in 69% of the vardenafil group and in 26% of 
the placebo group.62 Vardenafil was also effective in dia-
betic patients; the positive reply rate for the GAQ ques-
tions occurred in 72% of the vardenafil group and in 13% 
of the placebo group, and the IIEF EF domain score after 
treatment was 19 points and 12.6 points in the vardenafil 
and placebo groups, respectively; this was significantly 
higher in the vardenafil group than in the placebo group.63
　In a study that was conducted on 306 patients with ED 
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from Asian countries including Korea, the IIEF EF domain 
score, which was a primary efficacy endpoint, was shown 
to be 24.2 points in the vardenafil group and 15.9 points 
in the placebo group after a 12-week treatment, which 
showed a significant improvement in the EF in the varde-
nafil group.64
(4) Udenafil
　Udenafil is an oral PDE5 inhibitor that was developed 
by a Korean pharmaceutical company. It was released to 
the Korean market in 2005. It is available in doses of 100 
mg and 200 mg, and a dose of 50 mg, which was devel-
oped for daily administration, has been recently released 
to the market. It has a blood half-life of approximately 9.9 
hours, and its effect starts approximately 30 minutes after 
oral administration, and lasts for 12 hours. A high-fat diet 
and alcohol do not affect the pharmacokinetics of 
udenafil.65 In a Korean study that was conducted on 167 
patients who had ED based on various causes, the result of 
efficacy assessment using the IIEF EF domain score as a pri-
mary efficacy endpoint showed that the score increased 
by 7.52 points, 9.93 points, and 0.2 point in the 100 mg 
udenafil, 200 mg udenafil, and placebo groups, re-
spectively, after a 12-week treatment, which showed a sig-
nificant improvement of EF in the udenafil groups.66 In ad-
dition, in a study that was conducted on 104 patients with 
ED, the result of efficacy assessment using the SEP ques-
tion 3 (Did your erection last long enough for you to have 
successful intercourse?) as a primary efficacy endpoint 
showed a positive reply rate of 54.7% in the udenafil 
group, and 28.3% in the placebo group after a 12-hour 
drug administration.67
(5) Mirodenafil
　Mirodenafil is an oral PDE5 inhibitor that was the sec-
ond to be developed by a Korean pharmaceutical 
company. It is available in doses of 50 mg and 100 mg. It 
has blood half-life of approximately 2.5 hours, and its ef-
fect starts approximately 30 minutes after drug admin-
istration and lasts for 4 hours. A high-fat diet and alcohol 
do not affect the pharmacokinetics of mirodenafil.68 In a 
Korean study that was conducted on 119 patients who had 
ED based on various causes, the result of efficacy assess-
ment using the scores on questions 3 (frequency of pene-
tration) and 4 (frequency of maintaining an erection) of the 
IIEF questionnaire as primary efficacy endpoints showed 
that the scores for questions 3 and 4 were 4.4 points and 
3.9 points, respectively, in the mirodenafil group, and in 
3.1 and 2.5 points, respectively, in the placebo group after 
an 8-week administration, which showed a significant im-
provement of EF in the mirodenafil group.16 Mirodenafil 
administration was also effective in diabetic patients; the 
IIEF EF domain score increased by 9.3 points in the mir-
odenafil group and 1.4 points in the placebo group, which 
showed a significant improvement of EF in the mirodenafil 
group.69
(6) Avanafil
Avanafil is the oral PDE5 inhibitor that has been most re-
cently released to the Korean market. It is available in 
doses of 100 mg and 200 mg. It has a blood half-life of 10.6 
hours, and its effect starts approximately 15∼30 minutes 
after drug administration and lasts for 6 hours. A high-fat 
diet may delay avanafil absorption, but does not affect ab-
sorption quantity. In a 12-week dose-response study, 
which was conducted on more than 600 patients in the 
U.S., the result of efficacy assessment using the IIEF EF do-
main score, and SEP questions 2 and 3 as primary efficacy 
endpoints, showed that the IIEF EF domain score was 22.2 
and 12.8 points in the 200 mg avanafil and placebo 
groups, respectively, and that the positive reply rate for the 
SEP questions 2 and 3 was 77% and 57%, respectively, in 
the avanafil group, and 48% and 12%, respectively, in the 
placebo group, which showed a significant improvement 
of EF in the avanafil group.70 In a Korean study that was 
conducted on 208 patients with ED based on various caus-
es, the IIEF EF domain score increased by 8.5 and 8.8 
points in the 100 mg and 200 mg avanafil groups, re-
spectively, and by 3.5 points in the placebo group after a 
12-week administration. The increases were significantly 
higher in the avanafil groups than in the placebo group.71
(7) Selection of phosphodiesterase type 5 inhibitors 
and their preference
　The efficacy and tolerability of the six PDE5 inhibitors 
currently available in the Korean market have been vali-
dated in several objective studies. Based on these previous 
results, many domestic and international studies compar-
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ing the efficacy of PDE5 inhibitors and patient preference 
have been done. However, an objective comparison of 
the efficacy of and patient preference for each PDE5 in-
hibitor is limited due to the various inclusion criteria, dif-
ferences in the peak efficacy time and efficacy duration for 
each PDE5 inhibitor, as well as the difficulty in conducting 
a randomized blind study. Thus, the choice of PED5 in-
hibitors should be based on the patient’s experience under 
a physician’s guidance regarding the characteristics of 
each PDE5 inhibitor, whether it is a short-acting or 
long-acting agent, and adverse events.
(8) Use of phosphodiesterase type 5 inhibitors: on- 
demand versus daily medication
　In studies using animal models with ED, such as models 
of diabetes or cavernous nerve injury, daily administration 
of PDE5 inhibitors was found to preserve penile structure 
and function.72,73 In addition, daily administration has the 
advantage of allowing for spontaneity of sexual activity. In 
a clinical study that was conducted on patients with ED, 
daily administration of tadalafil and sildenafil improved 
endothelial function. The improved endothelial function 
was maintained for a certain period of time after the dis-
continuation of daily medication, but EF returned to its 
pre-treatment status. These findings indicate that the im-
provement of endothelial cell function by daily admin-
istration is not necessarily connected to the improvement 
of EF.74,75
　In a placebo-controlled study, in which 342 patients 
with ED received tadalafil (5 mg) daily for 12 weeks, the 
IIEF EF domain score after the treatment was shown to be 
23.7 and 15.1 points in the tadalafil and placebo groups, 
respectively. Also, the positive reply rate for the SEP2 
question was shown to be 86.8% and 60%, and the pos-
itive reply rate for the SEP3 question was shown to be 71% 
and 37.3% in the tadalafil and placebo groups, re-
spectively, which showed a significant improvement in 
the EF in the tadalafil group. Furthermore, the patients and 
their partners had high sexual satisfaction in the tadalafil 
group.76 In a Korean study, in which 239 patients with ED 
received udenafil at doses of 25 mg, 50 mg, and 75 mg dai-
ly for 12 weeks, EF was improved more in the udenafil 50 
mg and 75 mg groups than in the placebo group.77 In a 
long-term open-label trial, in which 234 and 238 patients 
with ED received tadalafil (5 mg) daily for one and two 
years, respectively, the IIEF EF domain score increased by 
10.4 and 10.8 points in the two groups, respectively. A to-
tal of 57.9% and 57.8% of the two groups had normal EF 
with an IIEF score of ≥26 points.78 However, following a 
4-week discontinuation of tadalafil after the 1-year 
open-label extension, the mean IIEF-EF domain score de-
clined markedly to a near-baseline level.78
　In a study that compared the efficacy of on-demand ad-
ministration of tadalafil (20 mg) versus daily admin-
istration of tadalafil (10 mg) in 141 patients who had ED for 
various reasons, EF was improved more in the daily ad-
ministration group than in the on-demand administration 
group.79 However, in a study that compared the efficacy of 
the on-demand administration of tadalafil (20 mg) versus 
the daily administration of tadalafil (5 mg) in patients who 
had ED after radiation therapy for prostatic cancer, the im-
provement of EF was shown to be similar between the two 
groups.80 In a study that compared the efficacy of on-de-
mand administration of vardenafil (10 mg) versus daily ad-
ministration of vardenafil (10 mg) in patients with mild or 
moderate ED, no difference in the improvement of EF was 
found between the two groups.81 Thus, an additional 
large-scale study that investigates drug efficacy according 
to the causes of ED is required in order to objectively com-
pare the efficacy of daily administration versus on-de-
mand administration of PDE5 inhibitors. It would be desir-
able to determine the administration method according to 
the preference and characteristics of patients.
(9) Treatment of patients non-responsive to phospho-
diesterase type 5 inhibitors
　Approximately 30∼35% of patients with ED were re-
ported to have no response or a poor response to PDE5 
inhibitors.82 In general, if no response is observed after 
PDE5 inhibitors are administered at their maximum dose, 
taken four or more times with proper sexual stimulation, 
patients are considered to be non-responsive to PDE5 
inhibitors.83 The most common cause of non-responsive-
ness to PDE5 inhibitors is inadequate drug medication. It 
is known that approximately 30∼50% of initially non-res-
ponders become responders via a proper prescription and 
education for correct use.82-86 The necessity of sexual stim-
ulation, drug-specific optimal administration time, and in-
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fluences by foods must be included in the education with 
a prescription. The correction of risk factors, such as dia-
betes, hypertension, and dyslipidemia, is generally rec-
ommended, but no concrete evidence that the correction 
of such risk factors increases responsiveness to PDE5 in-
hibitors is currently available.
　However, regular aerobic exercise was reported to im-
prove the efficacy of PDE5 inhibitors in a randomized con-
trolled study.45 In addition, testosterone replacement ther-
apy was reported to be effective in non-responders to 
PDE5 inhibitors who showed a low or lower normal tes-
tosterone level.87,88 Some patients were reported to be re-
sponsive after changing to another type of PED5 
inhibitor.89 Another study reported that daily admin-
istration of PDE5 inhibitors was effective in patients who 
were non-responsive to the on-demand administration of 
PDE5 inhibitors.86 However, no randomized place-
bo-controlled study has been conducted to support the 
aforementioned result. If patients are still non-responsive 
to PDE5 inhibitors, other treatment methods, such as a 
vacuum constriction device or intracavernous injection, 
should be applied.
(10) Safety and adverse effects of phosphodiesterase 
type 5 inhibitors 
　① Cardiovascular safety of phosphodiesterase type 5 
inhibitors: The results of various randomized controlled 
studies, open-label studies, and postmarketing surveil-
lance studies have shown that PDE5 inhibitors did not in-
crease the incidence of myocardial infarction. It was also 
shown that PDE5 inhibitors did not negatively affect the 
results of an exercise stress test conducted on patients 
with stable angina.90,91 The results of accumulated pre-
clinical and clinical studies support the potential benefit 
of PDE5 inhibitors in the treatment of cardiovascular 
disease.92
　② Common adverse effects of phosphodiesterase type 5 
inhibitors: Common complications caused by PDE5 in-
hibitors include headache, facial flushing, indigestion, na-
sal congestion, dizziness, visual disturbances, and myal-
gia. In general, these complications occur within 2 weeks 
after the administration of PDE5 inhibitors, and then spon-
taneously disappear over time. Thus, the discontinuation 
of PDE5 inhibitors due to complications is rare.
　③ Contraindicated drugs during phosphodiesterase 
type 5 inhibitor administration: If patients are taking or-
ganic nitrates (nitroglycerine, isosorbide mononitrate, or 
isosorbide dinitrate) or other nitrates, such as nicorandil, 
which are used as anti-angina agents, PDE5 inhibitors are 
contraindicated. If the aforementioned drugs are used 
with PDE5 inhibitors, life-threatening hypotension may 
occur due to excessive blood vessel relaxation caused by 
cGMP accumulation. If patients who have received PDE5 
inhibitors complain of chest pain, nitrates should be halt-
ed for at least 24 hours if they have received sildenafil and 
vardenafil, which have a short half-life, and for at least 48 
hours if they received tadalafil, which has a long half-life. 
Concomitant medication of antihypertensive agents with 
PDE5 inhibitors may decrease blood pressure. However, 
severe orthostatic hypotension rarely occurs. If an α- 
blocker for the treatment of benign prostatic hyperplasia is 
administered with PDE5 inhibitors, a precaution should 
be given, as the concomitant administration may cause or-
thostatic hypotension. Each product description of PDF5 
inhibitors includes precautions on concomitant use with 
α-blockers. PDF5 inhibitors should initially be ad-
ministered at a low dose to minimize adverse effects. In 
case patients do receive an α-blocker, it is recommended 
that they take sildenafil and vardenafil at least 4 hours and 
6 hours, respectively, after the administration of the α- 
blocker. In a Korean study, the concomitant medication of 
an α-blocker with udenafil or mirodenafil at an interval of 
6 hours was shown to be safe and without decreased 
blood pressure.93,94
2) Vacuum constriction devices 
　Vacuum constriction devices provide passive engorge-
ment of the corpora cavernosa together with a constrictor 
ring placed at the base of the penis. A cylinder is placed 
over the penis, air is pumped out with an attached pump, 
and the resulting tumescence is maintained by a con-
striction ring. Although vacuum constriction devices are 
highly effective in inducing erections, regardless of the eti-
ology of the ED (70∼90%), reported satisfaction rates 
vary widely from 27% to 94%.95 Satisfactory outcomes in-
crease if both patients and their partners sufficiently under-
stand the treatment method before using the device. In 
case patients are insufficiently responsive to oral drugs or 
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intracavernous injection therapy, vacuum constriction de-
vices can be used concomitantly. 
　Penile erections with these devices are not normal since 
they do not use physiological erection pathways. All ri-
gidity is distal to the constriction band and the crura are not 
involved in the erection, causing some degree of in-
stability, leaving a potential for pivoting at the base and of-
ten requiring manual assistance to insert the penis into the 
vagina. The common adverse events include pain, inability 
to ejaculate, bruising, and numbness, which occur in less 
than 30% of patients.96 To avoid serious adverse events, 
such as skin necrosis, the use of the devices should be lim-
ited to 30 minutes. Excessive negative pressure can cause 
bruising and hematoma, and to avoid injury to the penis, 
only devices containing a vacuum limiter should be used.
5. Second-line treatment: Intracavernous injection
　Intracavernous injection of vasodilators is used sec-
ondarily in patients in whom first-line therapies, such as 
oral PDE5 inhibitors or vacuum devices, have failed. 
PGE1 (alprostadil) alone, or a combination of papaverine, 
phentolamine, and PGE1 (bimix=papaverine+phentol-
amine, trimix=bimix+PGE1) is recommended.97 Verapa-
mil, vasoactive intestinal peptide, and forskolin can be ad-
ditionally mixed with the main drugs, but clinical data on 
these drugs are insufficient. Papaverine has a relatively 
high rate of complications, such as prolonged erection 
and cavernous fibrosis, and phentolamine induces a sig-
nificant penile erection when combined with papaverine 
or PGE1.97 PGE1 monotherapy has a high efficacy rate (≥
70%) and the lowest rate of prolonged erection (1%).98,99 
Disadvantages of this therapy include penile pain 
(approximately 50%), a relatively high cost, and low sta-
bility (decrease in efficacy after 3 months in a cold storage 
condition and one week at room temperature).100 In the 
comparative studies, bimix was found to be effective and 
inexpensive, while prolonged erection and cavernous fib-
rosis were more common, and the success rate was lower 
than that of trimix. Trimix was shown to have a better effi-
cacy rate (92%) and less pain, but a higher risk of pro-
longed erection and cavernous fibrosis compared to 
PGE1.101-103 In a multicenter study on lyophilized trimix 
(StandroⓇ; Shin Poong Pharm, Co. Ltd., Seoul, Korea) de-
veloped in Korea, the success rate per trial and per patient 
were 74.1% and 91.2%, respectively, whereas the com-
plication rate was less than 1%.104 The add-on of PDE5 in-
hibitors may achieve significant penile erection in patients 
who are non-responsive to trimix, but the risk of complica-
tions (33%), such as dizziness, might increase.105
　The self-injection dose of vasodilators is determined 
based on the overall consideration of a patient’s age, caus-
es and severity of ED, and penile size. For example, 
lyophilized trimix (StandroⓇ) is injected initially at a dose 
of 0.05∼0.15 ml depending on the age in patients with 
psychogenic or neurogenic ED, and at 0.2∼0.25 ml with 
increments of 0.02∼0.05 ml for organic ED. The drug is 
administered using a syringe with a 30-gauge needle or 
automatic injector on at least two-day intervals, but not to 
exceed three times a week. Once the initial injection dose 
is determined at the hospital, instructions should include 
the following: injection techniques, injection frequency, 
and potential complications (prolonged erection, pain, 
bleeding of the injection site, swelling, infection, and cav-
ernous fibrosis).97 These patients should be followed at an 
interval of 3∼6 months, to evaluate the efficacy and ad-
verse events, and to adjust the dosage.97 
　In general, the risk of prolonged erection (≥4∼6 hours) 
is greater in the early phase of injection therapy, and more 
frequently occurs when papaverine rather than PGE1 is 
used.97 If penile erection is persistent after puncture and 
aspiration of blood using a syringe with a 19-gauge nee-
dle, alpha-adrenergic agonists (phenylephrine, epinep-
hrine) are administered. Phenylephrine (10 mg/ml) is di-
luted up to 100∼500 μg/ml with normal saline, and then 
1 ml of the diluted solution is injected each time.106 
Epinephrine (1 mg) is dissolved in 1,000 ml of normal sal-
ine, and then 10∼20 ml of the diluted solution is injected 
intracavernosally at intervals of 5 minutes.107 If rigid erec-
tion persists with these methods, shunt surgery should be 
considered.108
　Although the success rates of intracavernous injection 
therapy were about 70∼85%, low treatment compliance 
and high drop-out rates (41∼68%) were observed. The 
majority of the drop-outs occurred within the initial 2∼3 
months.109-111 Of the 216 Korean patients with ED, 49.5% 
discontinued treatment, most drop-outs occurred within 
the first 1 month, and the most common cause was fear of 
injection.112
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6. Third-line treatment: penile prosthesis
　The penile prosthesis shows high patient satisfaction. As 
it is an invasive and irreversible treatment method, how-
ever, it should be considered as a last treatment option in 
patients with ED who are non-responsive to other treat-
ments or who cannot undergo other treatments due to ad-
verse effects. 
　Penile prostheses are classified into inflatable (2 or 3 
pieces) and non-inflatable types (semi-rigid). Most patients 
prefer the 3-piece inflatable penile prosthesis, which is 
most similar to a natural penile erection. A non-inflatable 
penile prosthesis has the disadvantages of constant penile 
rigidity, a hard texture, and a high risk of erosion, whereas 
it has the following advantages: ease of use by the patient, 
a relatively low cost, and a low malfunction rate. In the case 
that the inflatable penile prosthesis is economically bur-
densome or the patient has difficulty in using the hands due 
to stroke, a non-inflatable penile prosthesis can be consid-
ered as a first option. It was also reported to be suitable for 
elderly patients with a low frequency of sexual inter-
course.113 A non-inflatable penile prosthesis can be consid-
ered for inexperienced physicians in the case of difficulty in 
cavernous dilatation due to severe cavernous fibrosis or res-
ervoir insertion from a previous pelvic surgery. In a Korean 
study, a high patient satisfaction rate and low rate of compli-
cations were observed in spinal injury patients after a 
non-inflatable penile prosthesis was applied.114
　As a penile prosthesis insertion is an invasive and ex-
pensive surgery, proper consultation with patients and 
their partners is required before surgery. During the con-
sultation, information on other treatment options, types, 
and features of the penile prosthesis, and advantages and 
disadvantages, expected price, and potential complica-
tions of each prosthetic device should be sufficiently 
discussed. 
　The major complications of a penile prosthesis are me-
chanical failure and infection. The frequency of mechan-
ical failure has gradually decreased due to the ongoing im-
provements in the design of prosthetic devices. Thus, the 
frequency of mechanical failure of a 3-piece penile pros-
thesis (AMS 700CX/CXMTM [American Medical Systems, 
Inc., Minnetonka, MN, USA], Mentor Alpha ITM [Mentor 
Corp., Santa Barbara, CA, USA]), which has recently been 
in common use, was reported to be less than 5% in a 
five-year follow-up study.115,116 In a Korean study that re-
ported the results of a long-term follow-up on a 3-piece 
penile prosthesis (AMS 700CX/CXMTM), the success rates 
of the penile prosthesis 3 years, 5 years, and 10 years post-
operatively were shown to be 95%, 91%, and 75.5%, 
respectively.117 As infection is a serious complication that 
requires removal of the prosthesis, both physicians and 
patients should take precautions. If a proper technique 
and broad-spectrum antibiotics, including those for both 
Gram negative and positive bacteria, are used, the in-
fection rate should be 2∼3%. To further reduce the in-
fection rate, studies using a prosthesis containing anti-
biotics or a hydrophilic-coated prosthesis have been 
conducted.118,119 In the case of urinary tract infection or 
skin infection of the surgery site, the surgery should be 
delayed. To reduce the risk of infection, the surgery site 
should be shaved immediately before the surgery, and an-
tibiotics should be administered one hour before the sur-
gery, and then maintained 24∼48 hours after the surgery. 
If infection occurs, all prostheses, in principle, should be 
removed and antibiotic treatment should be performed, 
followed by reoperation 6∼12 months later. On the other 
hand, another study reported that the success rate was 
82% in patients who underwent penile prosthesis im-
plantation immediately after the removal of the infected 
prosthesis and sufficient cleaning using various types of 
antibiotics.120 Other known complications include pain, 
hematoma, erosion, self-expansion, penile shortening and 
fibrosis, urethral rash, and the displacement of the penile 
prosthesis.
7. Erectile dysfunction after radical prostatectomy 
　ED is a common complication of radical prostatectomy 
for prostate cancer. Its occurrence rate varies, ranging 
from 25% up to 75%.21 The major cause of ED after radical 
prostatectomy is the injury of the cavernous nerve that is 
located at the posterolateral aspect of the prostate. Nerve 
injury and subsequent ED seem to cause the structural and 
functional deformity of cavernous endothelial cells and 
smooth muscle cells.121 In the early 1980s, Walsh and 
Donker,122 and Walsh et al123 presented the concept of 
nerve-sparing radical prostatectomy, and reduced the in-
cidence of ED significantly by applying the technique. 
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Since then, the introduction of the new anatomical con-
cept of the neurovascular bundle, which is responsible for 
penile erection,124,125 and the development of surgical 
techniques using a laparoscope and robot,126,127 have fur-
ther reduced the incidence of ED. However, ED that oc-
curs after radical prostatectomy is still a major compli-
cation. The occurrence rate of ED after radical prostatec-
tomy significantly varies depending on the study. This dif-
ference is likely to be attributable to the difference in the 
characteristics of subjects and surgical techniques. In the 
case of bilateral nerve sparing surgery, the postoperative 
recovery of EF was shown to be better in patients who 
were young and had good EF before surgery.128,129
　The treatment of ED that occurs after radical prostatec-
tomy is similar to that used for the general ED population. 
Although, PDE5 inhibitors are the first-line treatment for 
radical prostatectomy-induced ED, the response rate to 
PDE5 inhibitors is lower in these patients than in the gen-
eral ED population. Patients who have undergone bi-
lateral nerve sparing show a better response to PDE5 
inhibitors. In a placebo-controlled study that was con-
ducted on 440 patients who had ED after bilateral nerve 
sparing radical prostatectomy, 10 mg and 20 mg of varde-
nafil were shown to improve EF (GAQ question) in 59.7% 
and 71.1% of the patients, respectively, which was sig-
nificantly higher than 11.5% in the placebo group.130 In a 
placebo-controlled study that was conducted on 303 pa-
tients, who had normal EF before surgery but had ED after 
bilateral nerve sparing radical prostatectomy, the post-op-
erative IIEF EF domain score was shown to be 17.7 and 
13.3 points in the tadalafil and placebo groups, respec-
tively. The positive reply rate to the SEP2 question was 
shown to be 53.9% and 32.4% and 40.5% and 19.4% to 
the SEP3 question in the tadalafil and placebo groups, 
respectively. The results showed a significant improve-
ment of EF in the tadalafil group.131
　A small-scale study conducted by Montorsi et al132 
showed that the recovery of EF can be improved if alprosta-
dil intracavernosal injection therapy is conducted immedi-
ately after nerve sparing radical prostatectomy, providing 
an important theoretical foundation to the concept of pen-
ile rehabilitation treatment. Although studies on the daily 
administration of PDE5 inhibitors have been frequently 
performed, few double-blind, placebo-controlled studies 
have been conducted so far. Furthermore, even with 
long-term administration of over 36 months, the efficacy 
was shown to be insignificant. These findings demonstrate 
the limitation from a cost-efficiency perspective.133
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